Discover
NTHI
Neonc Technologies Holdings, Inc.
3.37
1 x 2.95
2 x 5.39
bid
ask
+
0.10
3.06%
5 @ 04:00 PM
3.57 +0.20 (5.93%)
| Ytd | -59.25% | |
| 1y | -29.35% |
3.20
day range
3.48
3.00
52 week range
12.99
| Open | 3.29 | Prev Close | 3.27 | Low | 3.20 | High | 3.48 | Mkt Cap | 67.38M |
| Vol | 46.74K | Avg Vol | 98.62K | EPS | -1.23 | P/E | -2.75 | Forward P/E | N/A |
| Beta | N/A | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 4.66 | 200-d Avg | 7.55 | 1yr Est | 0.00 |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|
Profile
Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|